Naturally Pure Products Salvestrol Platinum

A natural rescue mechanism borrowed from plants

Salvestrol® are a class of natural plant derived compounds that support the body’s natural cell cycle to eliminate damaged cells while bypassing healthy functioning cells. Nesem extracted Salvestrols are metabolized by the CYP1B1 enzyme which is only activated in damaged cells to support regulation of the cell cycle.

• Plant derived compounds/molecules with a pharmacological rather than a chemical definition
• Supports elimination of aberrant cells 41
• Helps modulate chronic disease
• A cell rescue mechanism providing protection beyond antioxidant activity

Key Points

• Inadequate levels of Salvestrols are associated with unregulated over proliferation of abnormal cells
• Salvestrols are utilized as part of the body’s natural cell cycle regulation process
• Effect of Salvestrols is not through a cytotoxic response
• Selectivity; no effect on normal cells 49
• No interactions; can be used alongside conventional treatments with improved health outcomes and survival
• Salvestrols are not antioxidants but are anti-inflammatory and anti-fungal

Pharmacodynamics

• Escape first pass metabolism
• Cytochrome P450 enzyme1B1 (CYP1B1) – highly overexpressed in all DNA damaged cells, found to be specifically localized in these aberrant cells 1-12, 16,17,21,22,24,28,36,37
• Salvestrols are metabolized by CYP1B1 protein, being the substrate, within DNA damaged cells resulting in metabolites which drive cell regulation and apoptosis of damaged cells
• Metabolites may be associated with modulation of cellular mitotic replication, cell cycle blockade at G2/M DNA damage check point, initiation of apoptosis, tyrosine kinase inhibition

What is the NESEM® Advantage?

Naturally Pure Products has trademarked NESEMs® as their science - Naturally Elicited Specifically Extracted molecules an advanced technology developed and refined for over 25 years, to extract specific secondary plant metabolites through natural elicitation, using the plants natural defense mechanism in response to environmental conditions.

Salvacare is the proud distributor of these Nesem products in NZ, providing natural pure plant-based molecules to support the human body’s natural regulatory systems through:

• Anti-cancer activities
• Neurogenesis functions
• Anti-inflammatory activities
• Antioxidant activities / Beyond Antioxidant
• Cholesterol lowering ability

NESEM provides the technological advantage in harnessing the power of plants to benefit human health, well-being and quality of life.

What makes NESEM® extracts so different?

NESEM® extracts are extracted through a super or sub critical fluid extraction process, resulting in a more pure and specific extract with a potentially lower toxic and chemical residue. Super critical fluid extraction with CO2 is a clean method of extracting specific secondary plant molecules or phytoalexins (nesems®). The benefit of using Super Critical extraction means the use of chemical solvents are avoided, yielding more specific and cleaner molecules for use in our products

Background of CYP1B1 and Salvestrols

Identified as a result of multiple university projects over a 20-year period; the initial discovery was of the enzyme CYP1B1 being highly overexpressed in tumor cells. Since 1997 there have been many peer-reviewed published studies of over 3,300 samples in total, including 2,500 abnormal growths of many types, which have led to the identification of CYP1B1 enzyme being active in abnormal cells while normal functioning cells do not have the CYP1B1 enzyme.

Further research was undertaken through the Cancer Drug Discovery Group Project at De Montfort University with the aim to develop synthetic compounds to target the CYP1B1 enzyme, however they had very limited success. Subsequent investigation into plant sources lead to the discovery of natural plant derived compounds, Salvestrols and their affinity with the CYP1B1 enzyme.

Research includes human case studies and immunohistochemical studies of live cell lines from human biopsy tissue samples.

Salvestrols are metabolized by the CYP1B1 enzyme which produces a substrate to that drive cell regulation and apoptosis of damaged cells.

Ingredients A blend of key NESEM extracts from

Citrus bioflavonoids (Citrus sinensis) 300mg, Grape seed (Vitis vinifera) 75mg, Pumpkin (Cucurbita maxima) 75mg, Bulking agent Rice flour 50mg

Dosing Guide

SPLIT DOSING

To maintain the maximum therapeutic window split dosing is recommended where two thirds (⅔) of the total Salvestrol dose is taken upon waking and the remaining third (⅓) taken three hours later.

Therefore, if the recommended dose is 6 caps a day then 4 caps taken at 6am and 2 caps taken at 9am or 7am and 10am.

Split dosing has been found to be more effective than spreading the dose out throughout the day, given Salvestrols peak concentration is reached approximately 3 hours after initial dose by taking one third of the dose ad peak concentration is diminishing the body is able to maintain a higher concentration for a longer period of time.

Note: A number of physicians in Germany take the following approach: if the patient is not showing any response or is responding very slowly, three weeks after they should have reached a steady state of Salvestrol levels, (7-9 weeks after treatment has commenced); the dose should be doubled. The theory behind this is that if there is competition for the CYP1B1 binding site from other compounds, (also known as competitive inhibition), an increase in the relative concentration of Salvestrols will result in more of the Salvestrol compounds being available/metabolized.

Cytochrome P450 enzyme activity drops off after 3pm, therefore it is recommended to dose first thing in the morning when activity is at its highest. We advise dosing with Salvestrols before midday for best results.

Initial Loading Dose: 6 capsules per day (four capsules on waking followed by two capsules 3hrs later) for the initial 6-12 weeks or longer as needed or as prescribed by health provider. When Salvestrols are first introduced they will be taken up by the body until a steady state is achieved.

Active Modulation Dose: 3-6 capsules daily being two to four capsules in the morning on waking followed by one to two capsules 3hrs later

Maintenance Dose: 1-3 capsules daily being one to three capsules taken together in the morning on waking.

Preventative Dose:1-2 capsules daily being one to two capsules taken together on waking in the morning. Ongoing.

Note: one to two capsules daily in the morning is a great addition to a healthy approach to life, utilizing the anti-inflammatory and anti-fungal activity of Salvestrol capsules, supporting better health outcomes.

One capsule = 2,000 Salvestrol points

Initial loading dose

6 capsules daily for initial 6 – 12 weeks or as recommended by health care provider

Active Treatment 3 – 6 capsules daily Two thirds (⅔) of dose in the morning, remaining third (⅓) 3 hours later Ideally taken 30 minutes before food and with 500mg-1000mg Vitamin C daily

Remission /Maintenance 1 or 2 capsules daily

Considerations for increase dose requirements:

• Central Nervous System (CNS) involvement
• Aggressive / metastasised / Stage 4 diagnosis
• Impaired liver or bowel function
• Concurrent fungal infection
• Presence or use of compounds known to have an impact on expression of CYP1B1 or compete with Salvestrols.

Note: Daily Vitamin C is suggested to help support/optimize activity of Salvestrols, as an electron donor. We suggest 500mg – 1000mg daily.

Interactions/Contraindications

There are no known contraindications or interactions.

Concurrent use of Chemotherapy and Radiotherapy

There are no known contraindications or interactions between Salvestrol and chemotherapy or radiotherapy treatments. This includes oral, intravenous, or implanted forms. Please note that Salvestrols are not antioxidants.

A recent study (2022) in an Indian population indicated when NESEM extracts were used as an adjunct to standard cancer treatment (chemotherapy, radiotherapy and surgery or a combination of these therapies), the overall survival rate was better in the group using both NESEM extracts and receiving standard cancer treatment than using standard cancer treatment alone. The study concluded NESEM extracts improved cancer treatment. 55

Due to the various cardiotoxic cancer treatments, cardiovascular complications are frequently reported, a study by Carrera et al (2020), indicated that when the CYP1B1 is inhibited there is protection against chemotherapy-induced cardiotoxicity and chemo and radio resistance. As Salvestrols are metabolized by CYP1B1, it is through that this then inhibits the CYP1B1 capabilities thus protecting the cancer patient from cardiovascular complications. 56

Side Effects

No known side effects. Food based extracts.

Drug Interactions

• It is important to note that Salvestrols are not antioxidants

Professor Dan Burke has established through extensive research as a pharmacologist that there are no known contraindications or interactions between Salvestrol and any pharmaceutical medications.

Optimizing Effectiveness of Salvestrols

• Split dosing to extend therapeutic window
• Take away from other medications and supplements/herbal medicines to minimise competitive inhibition
• Minimize endocrine disruptors
• Improve diet where possible – organic, whole foods diet – reduce sugar and processed foods
• Support bioavailability through optimized liver, bowel and B-glucuronidase function Support key nutrient support/Cofactors
• Moderate exercise, breathing techniques - oxygenation

Key Nutrient Support/Cofactors

There are some key nutrients and cofactors that support the effectiveness of Salvestrols, given we know at times of chronic inflammation or DNA damage, there is a greater demand for these nutrients in the body. All key nutrients support the activity of Salvestrols with the CYP1B1 protein.

• Vitamin C - Our bodies have a greater demand for Vitamin C with chronic inflammation or disease, anyone with DNA damage or chronic inflammation is more than likely “running on the low end of normal” when it comes to available vitamin C (ascorbate) for support and protection within the body. Optimal vitamin C is key to supporting the activity of Salvestrol Capsules, through its antioxidant and electron donating ability.
• B Vitamins – in particular: Biotin (Vitamin H), Riboflavin (B2), Niacin (B3), and Cobalamin. Biotin has been shown to stimulate the expression of CYP1B1 and is a non-selective inducer of enzymes.
• Magnesium – the activity of CYP1B1 is reduced by 50% when levels of magnesium are inadequate. Iron – CYP1B1 utilizes iron at its core to oxidize substrates. Low levels of iron (anemia) are commonly present with those who are chronically unwell.
• Unrefined essential fatty acids (EFAs) - Those with a chronic illness/DNA damage, in the central nervous system, especially benefit from a combination of Salvestrols with ω-3 & 6, assists membrane transport. Independent research has shown the use of unrefined fatty acid supplements (represented by EyeQ and Efamol) may yield more favorable results.

Frequently Asked Questions

How long should my patient stay on Salvestrols?

Once a patient has reached remission our research shows continued use of Salvestrols using a maintenance dose with dietary/lifestyle modifications support the patient to remain in remission with improved long-term health.

What type of diet will support optimization of Salvestrols?

Adopting an organic diet is beneficial as organically grown produce (particularly heritage varieties) supply additional Salvestrol compounds whilst minimizing further ingestion of agrochemical inhibitors.

According to our most experienced and successful practitioners, implementation of an organic diet is the key factor; other dietary considerations are secondary, as multiple drastic dietary changes may lead to further stress on the patient and potentially have a negative effect on patient compliance overall.

What effects the function of the CYP1B1 enzyme?

CYP1B1 enzyme can be inhibited through a variety of environmental, dietary sources and herbal medicines. To support the optimization of Salvestrols effect on the CYP1B1 enzyme we recommend patients minimize exposure to the following environmental toxins where possible:

• Strobilurins (fungicides)
• Agrochemicals (pesticides, herbicides)
• Topical fungicides
• Smoking (carbon monoxide)

And avoid taking or reduce the following foods and herbal medicines in the morning when taking Salvestrols:

• Artificial and natural sweeteners (including stevia and sugar alcohols)
• Grapefruit (naringenin & hesperetin) ▪ Excessive juice consumption
• High dose Resveratrol (over 50mg per day)
• Apricot kernels and flaxseed (Vitamin B17 /Laetrile)
• St. John’s Wort (hypericin) ▪ Calcium-D-Glucarate
• Cannabis (cannabinoids CBD, CBN, THC)

If the patient is exposed to any of the above while taking Salvestrols we recommend you work with your patient to follow the above advice. However, if your patient has a glass of juice in the morning with breakfast then this is not going to invalidate the effects of Salvestrols.

My patient is taking CBD oil, can they still take Salvestrols?

Yes, CBD oil can be taken while taking Salvestrols, however, to reduce any competitive inhibition we recommend taking Salvestrols in the morning and CBD in the afternoon.

My patient is taking Medicinal Mushrooms, can they still take Salvestrols?

Yes, Medicinal Mushrooms oil can be taken while taking Salvestrols, however, to reduce any competitive inhibition we recommend taking Salvestrols in the morning and Medicinal Mushrooms in the afternoon.

What lifestyle changes will support optimization of Salvestrols?

Modest exercise, breathing exercises or oxygen supplementation (bottled-oxygen, hyperbaric oxygen chambers) undertaken when Salvestrols are at peak concentration in the body, (three to four hours after ingestion), will improve beneficial metabolism of Salvestrols. This is because Oxygen supplies electrons to the CYP enzymes for the metabolism of substrates (Salvestrols being the substrate here).

The peak therapeutic window between peak concentration of Salvestrols in the blood and the peak concentration of the Salvestrol metabolites in the blood is about two hours long. As recent laboratory studies have shown that an oxygen-rich environment stimulates healthy immune cells, 53 we recommend undertaking modest exercise, breathing exercise or oxygen supplementation three to four hours after initial morning dose as outlined in the table below.

</tr> </tr> </tr> </tr>

Time	Salvestrol use & increasing Oxygen use	Notes
Hour 0	Administer 2/3 of the daily Salvestrol dose:
Hour 1
Hour 2
Hour 3	Administer 1/3 of the daily Salvestrol dose:	Peak Salvestrol concentration in blood
Hour 4	Administer oxygen therapy or have patient engage in light exercise or breathing exercises for 10 minutes.	Peak Salvestrol concentration in cancer cells
Hour 5		Peak Salvestrol metabolite concentration in blood
Hour 6		Peak concentration of second dose of Salvestrols in blood
Hour 7	Administer oxygen therapy or have patient engage in light exercise or breathing exercises for 10 minutes.	Peak concentration of second dose of Salvestrols in cancer cells
Hour 8		Peak concentration of second dose of Salvestrol metabolite in blood

DNA damage in the lung and blood respond very well to Salvestrols when the environment is rich in oxygen.

My patient has skin lesions/fungal infection, will Salvestrols have any effect?

Yes, Salvestrols have been shown to modulate topical skin lesions and function infections. We recommend using LypoSalve topically in conjunction with Salvestrols for greater effect. Refer to LypoSalve for further information on how it can support skin lesions/fungal infections topically.

My patient is not feeling like they are getting any results and is feeling discouraged, should they stay on Salvestrols?

If the patient is feeling discouraged and may be thinking that their recovery is too slow; and you have worked through all the above with them, it is worth reminding the patient that “No change is good”, especially if their original prognosis was terminal. We have numerous reports of people who have been taking Salvestrols for many months and sometimes it is only after they have had an MRI or CT scan with results showing shrinkage or no DNA damaged cells detected that they realize that they are feeling better. We also have reports from practitioners and their patients who have now survived five years or more, after originally being informed they were terminal and have now been told that they are in remission.

References

CYP1B1 and Cancer Research References Murray, G.I., Taylor, M.C., McFadyen, M.C., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. (1997) 57: 3026-3031.

McFadyen, M.C., Breeman, S., Payne, S., et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. (1999) 47: 1457-1464.

Murray, G.I., Melvin, W.T., Greenlee, W.F., et al. Regulation, function and tissue-specific expression of cytochrome P450 CYP1B1. Ann Rev Pharmacol Toxicol. (2001) 41: 297-316.

Stanley, L.A., Ball, M.T., Eaden, J., et al. Cytochrome P450 CYP1B1 in the early stages of colon tumour development. Drug Metabol Rev. (2001) 33: 77.

Carnell, D., Smith, R., Daley, F., et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys. (2004) 58: 500-509.

Barnett, J.A., Urbauer, D.L., Murray, G.I., et al. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. (2007) 13: 3559-3567.

McFadyen, M.C.E., Cruickshank, M.E., Miller, I.D., et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer. (2001) 85: 242-246.

Tsuchiya, Y., Nakajima, M., Takagi, S., et al. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. (2006) 66: 9090-9098.

Hoang, T.T.V., Burke, M.D., Butler, P.C., et al. Cytochrome P450 1B1 (CYP1B1) expression in human cervical intraepithelial neoplasia. Br J Cancer. (2001) 85: 78.

Chang, H., Su, J., Huang, C.C., et al. Using a combination of cytochrome P450 1B1 and b-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detect Prevent. (2005) 29: 562–569.

Su, J., Lin, P., Wang, C., et al. Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res. (2009) 29: 509-515.

Tokizane, T., Shiina, H., Igawa, M., et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. (2005) 11: 5793-5801.

Haas, S., Pierl, C., Harth, V., et al. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer. (2006) 119: 1785-1791.

Gibson, P., Gill, J.H., Kahn, P.A., et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenosarcomas relative to normal colon: implications for drug development. Mol Cancer Ther. (2003) 2: 527-534.

Ragavan, N., Hewitt, R., Cooper, L.J., et al. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett. (2004) 215: 69-78.

Maecker, B., Sherr, D.H., Vonderheide, R.H., et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. (2003) 102: 3287-3294.

Chang, J.T., Chang, H., Chen, P., et al. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res. (2007) 13: 38-45.

McFadyen, M.C., Murray, G.I., and Melvin, W.T. Cytochrome P450 CYP 1B1 mRNA in normal human brain. J Clin Pathol. (1999) 52: 164.

Oyama, T., Morita, M., Isse, T., et al. Immunohistochemical evaluation of cytochrome P450 (CYP) and P53 in breast cancer. Front Biosci. (2005) 10: 1156-1161.

Vinothini, G., Letchoumy, P.V., Prathiba, D., et al. Immunohistochemical analysis of biomarkers in patients with adenocarcinoma of the breast: correlation with menopausal status and histological grade. Arch Med Sci. (2008) 4: 129–139.

Kumarakulasingham, M., Rooney, P.H., Dundas, S.R., et al. Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. (2005) 11: 3758-3765.

Greer, M.L., Richman, P.I., Barber, P.R., et al. Cytochrome P450 1B1 (CYP1B1) is expressed during the malignant progression of head and neck squamous cell carcinoma (HNSCC). Proc Am Cancer Res. (2004) 45: Abstract #3701.

McFadyen, M.C., Melvin, W.T., and Murray, G.I. Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer. (2004) 91: 966-971.

Furukawa, M., Nishimura, M., Ogino, D., et al. Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci. (2004) 95: 520-529.

Edwards, R.J., Adams, D.A., Watts, P.S., et al. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol. (1998) 56: 377–387.

Chang, T.K.H., Chen, J., Pillay, V., et al. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci. (2003) 71: 11-19.

Lin, P., Chang, H., Ho, W.L., et al. Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer. (2003) 42: 255-261.

Maecker, B., von Bergwelt-Baildon, M.S., Anderson, K.S., et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exptl Immunol. (2005) 141: 558-562.

Dhaini, H., Thomas, D., Giordano, T., et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncology. (2003) 21: 2481-2485.

Downie, D., McFadyen, M., Rooney, P., et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. (2005) 11: 7369-7375.

Bandiera, S., Weidlich, S., Harth, V., et al. Proteosomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol. (2005) 67: 435-443.

Test